menu search

SESN / SESN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Sesen Bio, Inc.

SESN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Sesen Bio, Inc.
New York, New York--(Newsfile Corp. - October 4, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Sesen Bio, Inc. ("Sesen Bio") (NASDAQ: SESN) between December 21, 2020 and August 17, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=20117&wire=5 Read More
Posted: Oct 4 2021, 17:45
Author Name: Newsfile Corp
Views: 111530

SESN News  

SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?

By Zacks Investment Research
November 30, 2022

SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?

SESEN BIO, INC. (SESN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. more_horizontal

Bradley Louis Radoff Discloses Activist Position in SESN / Sesen Bio

By 24/7 Wall Street
November 22, 2022

Bradley Louis Radoff Discloses Activist Position in SESN / Sesen Bio

Fintel reports that Radoff Bradley Louis has filed a 13D form with the SEC disclosing ownership of 6,000,000 shares of Sesen Bio Inc (SESN). more_horizontal

Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down

By Zacks Investment Research
July 19, 2022

Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down

Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange more_horizontal

Why Shares Of Sesen Bio Are Down 28% Today

By Benzinga
July 18, 2022

Why Shares Of Sesen Bio Are Down 28% Today

Sesen Bio Inc (NASDAQ: SESN) shares are trading lower by 28.9% at $0.66 Monday morning after the company announced that it has made the decision to v more_horizontal

Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US

By Benzinga
July 18, 2022

Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US

Based on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, more_horizontal

Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now

By PennyStocks
June 9, 2022

Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now

Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy? more_horizontal

Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April

By PennyStocks
April 14, 2022

Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now? more_horizontal

Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer

By Benzinga
December 9, 2021

Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer

Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive bladder can more_horizontal


Search within

Pages Search Results: